1. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon
- Author
-
Agnese Restuccia, Peter Schemmer, Ralf Bartenschlager, Silke Bender, Stefan Seitz, Katrin Schöneweis, Florian A. Lempp, Pascal Mutz, Ronald Koschny, Thomas Tu, Jamie Frankish, Thomas F. Baumert, Bingqian Qu, Marco Binder, Stephan Urban, Katrin Hoffmann, Christopher Dächert, Philippe Metz, Benjamin Schusser, Georgios Polychronidis, Institut de Recherche sur les Maladies Virales et Hépatiques (IVH), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Heidelberg University, German Centre for Infection Research (DZIF), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Heidelberg University Hospital [Heidelberg], L'Institut hospitalo-universitaire de Strasbourg (IHU Strasbourg), Institut National de Recherche en Informatique et en Automatique (Inria)-l'Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD)-Les Hôpitaux Universitaires de Strasbourg (HUS)-La Fédération des Crédits Mutuels Centre Est (FCMCE)-L'Association pour la Recherche contre le Cancer (ARC)-La société Karl STORZ, Nouvel Hôpital Civil de Strasbourg, and univOAK, Archive ouverte
- Subjects
0301 basic medicine ,HBsAg ,PRR ,Aucun ,Hepacivirus ,Virus Replication ,medicine.disease_cause ,Hepatocytes/drug effects/*immunology/virology ,Interferon ,Hepacivirus/drug effects/genetics/*immunology ,Coinfection ,Interferon-stimulated Gene ,RIG-I ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Gastroenterology ,Coinfection/drug therapy/immunology/virology ,virus diseases ,prr ,Antiviral Agents/*pharmacology ,cccDNA ,Hepatitis B ,Hepatitis C ,ddc ,3. Good health ,Hepatitis B virus/drug effects/genetics/*immunology ,rig-i ,Liver ,HBeAg ,Liver/cytology/immunology/virology ,Hepatitis B/drug therapy/immunology/virology ,medicine.drug ,Hepatitis B virus ,Hepatitis C virus ,Sciences du Vivant [q-bio]/Médecine humaine et pathologie ,Biology ,Antiviral Agents ,Interferons/*pharmacology ,03 medical and health sciences ,Immune system ,medicine ,Humans ,Innate/*immunology ,Virus Replication/drug effects ,Hepatology ,Immunity ,Viral/drug effects/immunology ,DNA ,Virology ,Immunity, Innate ,digestive system diseases ,030104 developmental biology ,Viral replication ,DNA, Viral ,Hepatocytes ,Interferons ,Hepatitis C/drug therapy/immunology/virology ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Background & Aims Hepatitis C virus (HCV) infection is sensitive to interferon (IFN)-based therapy, whereas hepatitis B virus (HBV) infection is not. It is unclear whether HBV escapes detection by the IFN-mediated immune response or actively suppresses it. Moreover, little is known on how HBV and HCV influence each other in coinfected cells. We investigated interactions between HBV and the IFN-mediated immune response using HepaRG cells and primary human hepatocytes (PHHs). We analyzed the effects of HBV on HCV replication, and vice versa, at the single-cell level. Methods PHHs were isolated from liver resection tissues from HBV-, HCV-, and human immunodeficiency virus–negative patients. Differentiated HepaRG cells overexpressing the HBV receptor sodium taurocholate cotransporting polypeptide (dHepaRGNTCP) and PHHs were infected with HBV. Huh7.5 cells were transfected with circular HBV DNA genomes resembling viral covalently closed circular DNA (cccDNA), and subsequently infected with HCV; this served as a model of HBV and HCV coinfection. Cells were incubated with IFN inducers, or IFNs, and antiviral response and viral replication were analyzed by immune fluorescence, reverse-transcription quantitative polymerase chain reaction, enzyme-linked immunosorbent assays, and flow cytometry. Results HBV infection of dHepaRGNTCP cells and PHHs neither activated nor inhibited signaling via pattern recognition receptors. Incubation of dHepaRGNTCP cells and PHHs with IFN had little effect on HBV replication or levels of cccDNA. HBV infection of these cells did not inhibit JAK-STAT signaling or up-regulation of IFN-stimulated genes. In coinfected cells, HBV did not prevent IFN-induced suppression of HCV replication. Conclusions In dHepaRGNTCP cells and PHHs, HBV evades the induction of IFN and IFN-induced antiviral effects. HBV infection does not rescue HCV from the IFN-mediated response.
- Published
- 2018
- Full Text
- View/download PDF